Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-11-20 M&A Activity
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
6 -- Sequana Medical - Board Report (ENG).pdf
M&A Activity Classification · 99% confidence The document is explicitly titled "REPORT OF THE BOARD OF DIRECTORS IN ACCORDANCE WITH ARTICLES 7:180, 7:191 AND 7:193 OF THE BELGIAN COMPANIES AND ASSOCIATIONS CODE". This structure, detailing justifications for a proposed transaction (issuance of new subscription rights and cancellation of existing ones, involving a loan agreement amendment) and referencing specific articles of a national corporate code, strongly indicates a formal report prepared by the board for shareholders regarding a significant corporate action. This aligns best with the general category of corporate governance or management reporting, but given the context of proposing a capital structure change (issuance of rights/shares) and the detailed justification required by law for overriding preferential subscription rights, it functions as a comprehensive management disclosure related to financing and corporate structure. Since it is a detailed report justifying a capital action rather than a simple announcement (like ER or RPA) or a general annual report (10-K), it fits best under the broad category of Management Reports (MDA) or potentially Capital/Financing Update (CAP). However, the document's primary function, as stated in the title and content, is the Board's formal report justifying the proposed capital transaction under specific legal articles. This level of detail and legal compliance points towards a Management Report (MDA) which often encompasses such detailed explanations of business decisions and financial implications, especially when related to financing terms. Reviewing the definitions: - 10-K: No, this is not the full annual report. - ER: No, this is not just an earnings release. - CAP: While it concerns capital, the document is a formal Board Report justifying the action, not just the announcement of the financing itself. - MDA (Management Reports): 'Management's detailed explanation of financial results, business trends, and outlook.' This document is a detailed explanation of a proposed transaction impacting capital structure, which is a key management responsibility. Given the explicit nature as a 'REPORT OF THE BOARD OF DIRECTORS' justifying a complex capital transaction (issuance of subscription rights tied to a loan agreement amendment), MDA is the most appropriate classification for this detailed explanatory document.
2024-11-20 English
6 -- Sequana Medical - Board Report (NL).pdf
Management Reports Classification · 99% confidence The document is titled "VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG ARTIKELEN 7:180, 7:191 EN 7:193 VAN HET WETBOEK VAN VENNOOTSCHAPPEN EN VERENIGINGEN" (Report of the Board of Directors pursuant to Articles 7:180, 7:191 and 7:193 of the Code of Companies and Associations). This structure, detailing the justification for a proposed transaction (the issuance of new subscription rights and the cancellation of old ones, involving a waiver of pre-emptive rights for a lender, Kreos), is characteristic of a formal report presented to shareholders for approval at a General Meeting, as mandated by Belgian corporate law (Wetboek van vennootschappen en verenigingen). This type of document, which explains complex financing/capital structure changes and seeks shareholder approval by waiving pre-emptive rights, strongly aligns with the requirements for a document related to capital structure changes or a formal report justifying such actions, often preceding or accompanying a proxy statement or AGM materials. Given the detailed explanation of financing terms (Kreos Loan Facility, subscription rights, conversion prices) and the explicit reference to presenting proposals to the BAV (Extraordinary General Meeting of Shareholders), it is a comprehensive report justifying a capital/financing action that requires shareholder consent. While it discusses financing (CAP), its primary function is the formal Board Report justifying the capital action and the waiver of pre-emptive rights, which is often covered under broader governance/shareholder information, but the core subject is the capital transaction itself. Since it is a detailed report justifying a capital transaction and the waiver of pre-emptive rights, it fits best under Capital/Financing Update (CAP) or potentially Governance Information (CGR) or Proxy Solicitation (PSI). However, the focus on the loan facility modification and the issuance of new rights makes CAP the most relevant primary category for the underlying economic event being reported on. Since it is a formal report justifying the transaction, and not just a brief announcement, it is not RPA or RNS. It is a detailed justification report, which is more substantial than a simple ER or MRQ. Given the context of financing and capital structure changes being detailed by the Board, CAP is the most appropriate fit among the provided options for this type of detailed justification document related to debt conversion/warrants.
2024-11-20 Dutch
1 -- EGM Sequana Medical - Convening Notice (ENG).pdf
AGM Information Classification · 98% confidence The document is explicitly titled 'INVITATION EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING' and details the agenda for this meeting, which includes proposals regarding the cancellation and issuance of subscription rights (a capital/financing structure change). This content is characteristic of materials presented or voted upon at a General Shareholders' Meeting. Since it is an invitation detailing the agenda and proposed resolutions for a shareholder meeting, it strongly aligns with the purpose of an Annual General Meeting (AGM) or an Extraordinary General Meeting (EGM) document, which falls under the AGM-R category. It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA).
2024-11-20 English
1 -- EGM Sequana Medical - Convening Notice (NL).pdf
AGM Information Classification · 98% confidence The document is explicitly titled "UITNODIGING" (Invitation) for a "BUITENGEWONE ALGEMENE AANDEELHOUDERSVERGADERING" (Extraordinary General Shareholders' Meeting) scheduled for December 20, 2024. It details the agenda items, which involve proposals for shareholder approval regarding the cancellation of existing subscription rights and the issuance of new subscription rights to a specific party (Kreos). This content—an invitation and agenda for a shareholder meeting—is characteristic of materials related to an Annual General Meeting (AGM) or a similar formal shareholder gathering. Since it is an invitation to a general meeting, the most appropriate classification is AGM-R (AGM Information), even though it is an 'Extraordinary' meeting, as it deals directly with shareholder governance and meeting procedures.
2024-11-20 Dutch
20241114 -PR - Belfius Loan Conversion (ENG).pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled "SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES" and details a specific increase in share capital, the number of issued shares, and the potential shares issuable upon the exercise of various options and warrants. This directly relates to changes in the company's capital structure. The document is explicitly labeled as a "PRESS RELEASE REGULATED INFORMATION." This content aligns perfectly with the definition of 'Capital/Financing Update' (CAP), which covers updates on fundraising, financing activities, or capital structure changes. It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA).
2024-11-14 English
20241114 -PR - Belfius Loan Conversion (NL).pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled with headers indicating it is a 'PERSBERICHT GEREGLEMENTEERDE INFORMATIE' (Regulated Information Press Release) dated November 14, 2024. The core content explicitly announces changes to the company's capital structure: an increase in capital and an increase in the number of issued and outstanding shares due to the conversion of debt claims into equity ('inbreng in natura van schuldvorderingen'). It also details the resulting changes in outstanding subscription rights, options, and warrants. This directly relates to changes in the company's capital structure and share count. The most fitting category is 'Share Issue/Capital Change' (SHA). It is not a general Earnings Release (ER), a comprehensive Interim Report (IR), or a simple announcement of a report (RPA).
2024-11-14 Dutch

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.